$175M financing will support development of in vivo CAR-T therapies
Drug Discovery World
MARCH 20, 2024
The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing.
Let's personalize your content